Celyad (CYAD)
(Delayed Data from NSDQ)
$0.47 USD
0.00 (0.00%)
Updated May 18, 2023 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Celyad SA [CYAD]
Reports for Purchase
Showing records 1 - 20 ( 56 total )
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
2021 Results; Additional FDA Feedback On KEYNOTE-B79 Clinical Hold Expected Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
KEYNOTE-B79 Trial Voluntarily Halted After Patient Fatalities; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
First Patient Dosed in the Phase 1b KEYNOTEB79 Combination Trial of CYAD-101 and Keytruda
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Lowering Price Target Due to Recent Capital Raise
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
3Q21 Results; CYAD-211 Clinical Update Expected at ASH; KEYNOTE-B79 Anticipated to Initiate by YE21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
1H21 Results; CYAD-211 Data Update Expected by YE2021; Lowering PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Initial CYAD-211 Data in EHA Abstract Look Promising
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
1Q21 Results; Additional alloSHRINK Data Expected in Mid-2021; Lowering PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
FY20 Results; A Busy Quarter Ahead With CYAD-211 and CYAD-101 Data Anticipated 2Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
CYAD-02 and CYAD-211 Updates at ASH; CYAD-01 Discontinued; Lowering PT by $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
Dosing Begins in Phase 1 Trial of Allogeneic BMCA CART-T Candidate CYAD-211
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Celyad SA
Industry: Medical - Biomedical and Genetics
3Q20 Business Update; 2021 Could Be Time for Non-Gene Edited Allogeneic Therapies to Shine
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E